James Park

FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC

The FDA approved capivasertib plus abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The move creates a new catalyst for AstraZeneca’s Truqap and adds a biomarker-defined prostate cancer use to track.

BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence

BioCryst Pharmaceuticals is presenting new clinical data and real-world evidence for ORLADEYO (berotralstat) in hereditary angioedema. The update matters because it expands the evidence base around an FDA-approved oral prophylactic option for adults and pediatric patients 2 years and older.

Truqap gains US approval in PTEN-deficient metastatic prostate cancer

AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.

Duty of care at oncology conferences spotlights planetary health research

Nature’s June 11, 2026 editorial argues for better amplification of planetary health research at oncology conferences. The piece links climate and environmental disruption to cancer risk and frames the issue for cancer-care stakeholders.

Synthetic real-world data reshapes oncology trial decision-making

Synthetic real-world data is being positioned to support oncology clinical trials by helping construct external control groups. Evidence also points to frameworks for evaluating how generalizable oncology randomized trial results are to real-world practice.

EMA approved 104 human medicines in 2025: what changed

EMA recommended 104 medicines for marketing authorisation in 2025, with 38 new active substances and a record biosimilar share. The update matters for BD teams, investors, and analysts tracking EU regulatory catalysts and near-term competitive readouts.

CHMP backs nerandomilast for IPF and PPF in EU

The EMA’s CHMP has issued a positive opinion recommending marketing authorization for Jascayd (nerandomilast) in the EU for adults with IPF and PPF. For BD teams and investors, the key catalyst is the next European Commission decision and how the asset fits into the fibrosis treatment landscape.

Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

This plan organizes a tightly sourced Eye drugs list around dry eyes, glaucoma, and eye infections. It keeps the focus on what the evidence confirms and avoids unsupported market or investment claims.

EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors

JLL's EMEA 2026 Life Sciences Industry & Cluster Report highlights strong public market performance, rising venture capital flows, and the transformative impact of AI on European life sciences clusters. The analysis provides actionable intelligence for pharma business development teams and investors navigating the evolving landscape.

Federal Court Litigation on Reproductive Health: Rare Disease Implications

This analysis examines recent federal court litigation involving reproductive health and rights, with a specific focus on implications for rare disease drug development and regulatory pathways. It provides decision-useful insights for pharma business development teams, investors, and analysts tracking FDA policy changes.

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

Data harmonization is the process of combining data across different sources and sites to enable comparison across studies. AI-driven tools are now transforming this critical bottleneck, reducing manual errors and accelerating clinical research.

European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma

The ESMO-EURACAN clinical practice guidelines now include Delcath's CHEMOSAT hepatic delivery system as a recommended liver-directed therapy for metastatic uveal melanoma. This decision, supported by two Phase 3 trials, strengthens the therapy's regulatory and commercial positioning in Europe.

Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma

The EMA's CHMP issued multiple positive opinions for new medicines and label extensions in late January, setting the stage for European launches. Meanwhile, FDA novel drug approvals continue to shape the 2026 pipeline. This round-up covers the key decisions and their commercial impact.

Novel Muscle-Active Agents: A Regulatory Perspective on Sarcopenia

This article provides a regulatory perspective on the development of novel muscle-active agents for sarcopenia, focusing on myostatin and activin A inhibitors. It covers key biological targets, regulatory considerations, and implications for pharmaceutical teams.

Health News Round Up: Diabetes, Vaping, and Biologics – What Pharma Teams Need to Know

Recent research reveals a significant association between vaping and increased risk of prediabetes and type 2 diabetes. This roundup analyzes the implications for pharma teams monitoring diabetes drug development and market dynamics.

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates

DelveInsight’s latest pipeline report reveals over 25 companies developing 30+ therapies for myasthenia gravis, with FcRn blockers and CAR-T therapies leading innovation. The report highlights key regulatory updates, biomarker progress, and the emerging concept of MG 'age' and 'stage'.

India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma

The India-Oman Comprehensive Economic Partnership Agreement (CEPA) entered into force on June 1, 2026, granting Indian pharmaceutical exports zero-duty access on 98% of tariff lines and a 90-day fast-track approval pathway for drugs already approved by the USFDA, EMA, UK MHRA, or TGA. The deal also includes mutual recognition of GMP standards and simplified compliance procedures, significantly reducing market access barriers for Indian drugmakers.

Nika Pharmaceuticals Inc OTCQB NIKA June 2026 Update: Key Developments and Strategic Implications

Nika Pharmaceuticals Inc (OTCQB: NIKA) is in active investor discussions and reported a Q1 2026 net loss of $13,359 with only $1,530 cash, raising substantial doubt about its ability to continue as a going concern. This update provides a structured analysis for pharma business development teams and investors.

Moderna Stock Rises as EMA Committee Backs New RSV Vaccine: Key Implications for Investors and BD Teams

Moderna Inc. stock (MRNA) rose 5.9% after an EMA committee backed its new RSV vaccine candidate. This analysis explains what changed, why it matters for pharma BD and investors, and what to watch next.

Florian Lordick Elected ESMO President 2029–2030: What Pharma Teams Should Watch

Professor Florian Lordick has been elected President of the European Society for Medical Oncology (ESMO) for the 2029–2030 term. This analysis outlines the timeline, Lordick's background, and strategic implications for pharma teams tracking ESMO's evolving priorities.

Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications

Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.

Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data

OST-HER2, a novel cancer therapy, is set for a 2026 EMA review following promising survival data. This article covers key takeaways, regulatory details, and strategic implications for pharma teams and investors.

CHMP May 2026 Output: A New Era in Drug Approvals

The CHMP May 2026 output marks a structural shift in European drug approvals, with implications for pharma BD teams, investors, and analysts. This article covers key takeaways, the development with dates and sources, and FAQs based on EMA guidance.

Pharma People on the Move: Spring 2026 Roundup — Regulatory Updates

Spring 2026 brings notable pharma executive moves and EMA regulatory updates. This roundup analyzes key appointments, the evolving drug approval process in Europe, and what BD teams and investors should watch next.